AGIO Stock: Price, Earnings History and SEC Filings
Agios Pharmaceuticals, Inc. (AGIO) last traded at $30.55, down 17.94% on the latest session and down 8.1% over the past month. In its most recent reported quarter (Jun 2026) earnings per share were $-1.69 against an analyst estimate of $-1.86, a beat of 9.1%.
$30.55 -17.94%
1 month-8.12%
52-week high$46.00
52-week low$22.24
Volume3.09M
ExchangeNasdaqGS
Price data from Yahoo Finance, as of Oct 30, 2026. May be delayed.
AGIO earnings history
| Quarter | Reported | EPS | Estimate | Surprise |
|---|---|---|---|---|
| Jun 2026 | Jul 30, 2026 | $-1.69 | $-1.86 | +9.14% |
| Mar 2026 | Apr 29, 2026 | $-1.69 | $-1.81 | +6.63% |
| Dec 2025 | Feb 12, 2026 | $-1.85 | $-1.97 | +6.09% |
| Sep 2025 | Oct 30, 2025 | $-1.78 | $-1.93 | +7.77% |
AGIO beat the analyst EPS estimate in 4 of its last 4 reported quarters. Source: Nasdaq.
Latest SEC filings for AGIO
SEC filing data is not available right now. You can search for AGIO on SEC EDGAR.
AGIO news
- Agios Sinks 18% as FDA Delays Sickle Cell Drug Decision to 2027 Despite Being “Launch-Ready”Oct 30, 2026 · tikr.com
- Agios Announces New PDUFA Goal Date of February 1, 2027, for Mitapivat Sickle Cell Disease sNDA; Company Is Launch-Ready and in Labeling Discussions with FDAOct 30, 2026 · finance.yahoo.com
- Agios Pharmaceuticals (AGIO) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 ReleaseOct 29, 2026 · finance.yahoo.com
- LENZ Therapeutics, Inc. (LENZ) Reports Q3 Loss, Misses Revenue EstimatesOct 28, 2026 · finance.yahoo.com
- DHR Q3 Earnings Beat on Biotechnology Strength, Sales in LineOct 21, 2026 · finance.yahoo.com
- Did Priority Review Just Shift Agios Pharmaceuticals' (AGIO) Investment Narrative?Oct 20, 2026 · finance.yahoo.com
- A Phase 3 Win and a 130% Takeover Premium Lit Up Rare Blood-Disease Stocks on MondayOct 20, 2026 · finance.yahoo.com
- FDA Decision Watch: What Investors Need To Know About Four Upcoming Drug RulingsOct 19, 2026 · stocktwits.com
About Agios Pharmaceuticals, Inc.
Agios Pharmaceuticals, Inc. (AGIO) is a US-listed public company on Nasdaq.